Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
9.1.2020 15:00:00 EET | Business Wire | Press release
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway.
“The impressive preclinical studies at Enleofen have revealed the potential of IL-11 blockade to treat a broad range of diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We are excited to have these monoclonal antibodies in our pipeline and have the opportunity to accelerate their path to many patients whose needs are not met by current treatments.”
IL-11 is a cytokine, a protein certain cells of the body use to communicate, and plays a key role in fibro-inflammatory conditions. Blocking IL-11 action has been shown to inhibit disease across many organs (liver, lung, kidney, retina, bowel, heart and skin). In preclinical studies, antibody-based IL-11 antagonists were able to prevent and reverse inflammation and fibrosis, and restore organ function.
Enleofen is a spin out company from the National Heart Centre Singapore (NHCS) at SingHealth and Duke-NUS Medical School under the SingHealth Duke-NUS Academic Medical Centre (AMC), Singapore and exclusively licensed a suite of patents and number of antibody products when it was founded in 2017, from the AMC. Subsequent to this, Enleofen has built an extensive anti-IL-11 antibody platform and advanced its drug development programs towards the clinic. Boehringer Ingelheim will now develop this platform further and plans to work jointly with scientists at the AMC to accelerate the platform into clinical development. The initial focus will be on novel therapies for patients with NASH and ILDs, two of Boehringer Ingelheim’s core disease focus areas, with a potential to expand into further fibro-inflammatory conditions based on IL-11’s central role in disease.
“Enleofen is very excited to engage Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D to develop further anti-IL-11 therapies to begin to address the unmet medical needs of patients worldwide,” said Prof Stuart Cook, Director and co-founder of Enleofen. “The preclinical data across a range of conditions are unprecedented and this new approach of targeting IL-11 could be a game changer”.
The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases. Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies. Under the terms of the agreement, Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones.
For references and notes to editors, please visit:
http://www.boehringer-ingelheim.com/press-release/fibrotic-diseases-partnership-enleofen
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005346/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Enleofen
Charu Srivastava
charu@redhill.asia
+65 91810614
Mariyam Haider
mariyam@redhill.asia
+65 86056752
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAGA FEI Expands Its Software-Embedded Bluetooth Low Energy Module Lineup with ES4L15MA1 and EC4L15MA119.8.2026 17:00:00 EEST | Press release
KAGA FEI Co., Ltd., a global provider of advanced short-range wireless modules, announced today the development of the ES4L15MA1 and EC4L15MA1 Bluetooth Low Energy modules with embedded software for wireless communication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802953307/en/ ES4L15MA1 (left) and EC4L15MA1 (right) sample modules These products are versions of KAGA FEI’s ES4L15BA1 and EC4L15BA1 wireless modules with embedded software, which use Nordic Semiconductor’s nRF54L15. Because the modules include the functions required for Bluetooth Low Energy communication, device manufacturers can develop products in a shorter period without having to develop wireless communication software from scratch. The modules help reduce software development workloads, shorten product development cycles, and lower development costs for a wide range of IoT devices. The need for wireless connectivity in IoT applications is growing acr
Xsolla Introduces Integrated Backend and Global Payment Solutions for Games, With Founding Partner AccelByte19.8.2026 16:00:00 EEST | Press release
Xsolla, a global video game commerce company, today introduced integrated backend solutions for game developers through a founding partnership with AccelByte, a fully managed extensible games backend platform, and opened a closed testing program for a combined solution that pairs AccelByte Gaming Services (AGS) with Xsolla's global payments and monetization tools. Select developers can now apply for early access and help shape the integration ahead of its broader launch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819624666/en/ Graphic: Xsolla As studios scale live games across PC, mobile, console, and the web, managing player persistence, gaming backend, and global transactions adds cost and slows launches. Through the founding partnership with AccelByte, Xsolla brings AccelByte's backend services together with its own payments and monetization in one integrated stack, so studios no longer need to stitch separate solu
Corpay Cross-Border Named the Official FX Partner of European T20 Premier League19.8.2026 15:30:00 EEST | Press release
Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with the European T20 Premier League (“ETPL”), a new franchise-based tournament sanctioned by the International Cricket Council, created to establish Europe as a dynamic force in the global T20 landscape. Under the agreement, Corpay becomes EPTL’s exclusive and Official Foreign Exchange (FX) Partner, along with being an Official Partner. As the EPTL’s exclusive foreign exchange partner, Corpay Cross-Border will provide the league with comprehensive FX risk management solutions to help mitigate foreign exchange exposure arising from its day-to-day business activities. Corpay Cross-Border’s award-winning platform will also enable the EPTL to streamline global payments through a single point of access. “Corpay Cross-Border is thrilled to be named the exclusive and official FX partner of the European T20 Premier League,” said Brad Loder
Mary Kay Accelerates Beauty Innovation and Digital Transformation19.8.2026 15:00:00 EEST | Press release
Mary Kay Inc. (“Mary Kay”), global iconic leader in beauty and entrepreneurship, announced today transformative business milestones, inviting the next generation to engage with a modernized Mary Kay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819989520/en/ Ryan Rogers, Chief Executive Officer of Mary Kay Inc. (Image Credit: Mary Kay Inc.) Statement fromRyan Rogers, Chief Executive Officer of Mary Kay: “We are re-defining the moment for Mary Kay. We are investing in technology and research to create seamless digital experiences while preserving the personal connections and sense of community that have always set Mary Kay apart. From the launch of Mary Kay My Shop to next-generation product innovation and purpose-driven impact, each milestone reflects the momentum behind our transformation. Building on more than 60 years of entrepreneurial legacy, we are reimagining how consumers engage with Mary Kay, meeting them where
Xceedance Appoints Insurance and Technology Executive Adrian Spieler to Board of Directors19.8.2026 15:00:00 EEST | Press release
Xceedance, a global provider of technology-driven business solutions for the insurance industry, today announced the appointment of Adrian Spieler to its Board of Directors, effective immediately. Spieler brings more than 30 years of experience across reinsurance, insurance, and asset management to the Xceedance board. He has served as Chief Operating Officer at Convex Insurance, a leading specialty insurer and reinsurer, since its launch in 2019. Before Convex, he spent 17 years at Swiss Re in a series of senior leadership positions, and later served as Group Chief Administrative Officer at Catlin and as Chief Enterprise Operations Officer and Chief Platform Officer, Insurance, at XL Catlin. As a member of the Xceedance Board of Directors, he will provide strategic guidance, set organizational goals, and measure success as the organization continues its high-growth trajectory. “Technology-enabled transformation is reshaping the insurance and reinsurance industries,” said Spieler, “and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom